問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Search Result

Search Result

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

China Medical University Hospital

List

1858Cases

2008-10-22 - 2010-10-22

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Terminated5Sites

2009-07-01 - 2012-08-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
9Sites

Terminated9Sites

2010-02-01 - 2011-10-30

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
11Sites

Terminated11Sites

2010-05-01 - 2013-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
15Sites

Terminated15Sites

2009-10-01 - 2012-01-31

Phase I/II

  • Condition/Disease

  • Test Drug

Participate Sites
10Sites

Study ended10Sites

2012-03-02 - 2014-08-31

Phase III

LUX-Lung 8: A randomized, open-label Phase III trial of afatinib versus erlotinib in patients with advanced squamous cell carcinoma of the lung as second-line therapy following first-line platinum-based chemotherapy

  • Condition/Disease

    Lung cancer

  • Test Drug

    BIBW 2992 (Afatinib)

Participate Sites
8Sites

Terminated8Sites

2011-12-07 - 2014-06-30

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Terminated6Sites

2011-09-01 - 2013-09-01

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Terminated8Sites

2011-04-15 - 2013-03-31

Phase I

A phase I dose escalation trial of weekly intravenous administrations of BI 836845 in patients with advanced solid cancers with repeated administrations in patients showing clinical benefit

  • Condition/Disease

    advanced solid cancer

  • Test Drug

    BI 836845

Participate Sites
3Sites

Terminated3Sites

2011-04-07 - 2014-05-31

Phase III

A phase III, randomised, double-blind and placebo-controlled study of once daily BI 201335 for 12 or 24 weeks in combination with pegylated interferon-α and ribavirin in treatment-naïve and prior relapser patients with genotype 1 chronic hepatitis C infection.

  • Condition/Disease

    Hepatitis C virus

  • Test Drug

    BI 201335

Participate Sites
5Sites

Terminated5Sites

1 174 175 176 177 178 186
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB